Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids-Reference-Cited by-同舟云学术

Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids

Published:2013-07-04 Issue:10 Volume:56 Page:2266-2274
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

Orešič Matej,Hyötyläinen Tuulia,Kotronen Anna,Gopalacharyulu Peddinti,Nygren Heli,Arola Johanna,Castillo Sandra,Mattila Ismo,Hakkarainen Antti,Borra Ronald J. H.,Honka Miikka-Juhani,Verrijken An,Francque Sven,Iozzo Patricia,Leivonen Marja,Jaser Nabil,Juuti Anne,Sørensen Thorkild I. A.,Nuutila Pirjo,Van Gaal Luc,Yki-Järvinen Hannele

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/article/10.1007/s00125-013-2981-2/fulltext.html

Reference46 articles.

1. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221–1231

2. Targher G (2007) Non-alcoholic fatty liver disease as a determinant of cardiovascular disease. Atherosclerosis 190:18–19, author reply 20–11

3. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK (2009) NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 104:861–867

4. Kotronen A, Yki-Jarvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27–38

5. Van Gaal LF, Mertens IL, de Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444:875–880

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Distinct changes in serum metabolites and lipid species in the onset and progression of NAFLD in Obese Chinese;Computational and Structural Biotechnology Journal;2024-12

2. Diagnostics and omics technologies for the detection and prediction of metabolic dysfunction-associated steatotic liver disease-related malignancies;Metabolism;2024-12

3. Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases;Journal of Hepatology;2024-08

4. Lipid Metabolism in MASLD and MASH: from mechanism to the clinic;JHEP Reports;2024-08

5. Dysfunctional VLDL metabolism in MASLD;npj Metabolic Health and Disease;2024-07-22